Antibodies against Anthrax Toxins: A Long Way from Benchlab to the Bedside
Open Access
Abstract
Anthrax is an acute disease caused by the bacterium Bacillus anthracis, and is a potential biowarfare/bioterrorist agent. Its pulmonary form, caused by inhalation of the spores, is highly lethal and is mainly related to injury caused by the toxins secretion. Antibodies neutralizing the toxins of B. anthracis are regarded as promising therapeutic drugs, and two are already approved by the Federal Drug Administration. We developed a recombinant human-like humanized antibody, 35PA83 6.20, that binds the protective antigen and that neutralized anthrax toxins in-vivo in White New Zealand rabbits infected with the lethal 9602 strain by intranasal route. Considering these promising results, the preclinical and clinical phase one development was funded and a program was started. Unfortunately, after 5 years, the preclinical development was cancelled due to industrial and scientific issues. This shutdown underlined the difficulty particularly, but not only, for an academic laboratory to proceed to clinical development, despite the drug candidate being promising. Here, we review our strategy and some preliminary results, and we discuss the issues that led to the no-go decision of the pre-clinical development of 35PA83 6.20 mAb. Our review provides general information to the laboratories planning a (pre-)clinical development.Keywords
Funding Information
- Direction Générale de l'Armement (2010.94.092)
This publication has 40 references indexed in Scilit:
- Mapping the Epitopes of a Neutralizing Antibody Fragment Directed against the Lethal Factor of Bacillus anthracis and Cross-Reacting with the Homologous Edema FactorPLOS ONE, 2013
- Isolation and Characterisation of a Human-Like Antibody Fragment (scFv) That Inactivates VEEV In Vitro and In VivoPLOS ONE, 2012
- Antibodies against Anthrax: Mechanisms of Action and Clinical ApplicationsToxins, 2011
- A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineeringmAbs, 2010
- Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activityBMC Biotechnology, 2009
- Noncapsulated Toxinogenic Bacillus anthracis Presents a Specific Growth and Dissemination Pattern in Naive and Protective Antigen-Immune MiceInfection and Immunity, 2007
- High-Affinity, Human Antibody-Like Antibody Fragment (Single-Chain Variable Fragment) Neutralizing the Lethal Factor (LF) of Bacillus anthracis by Inhibiting Protective Antigen-LF Complex FormationAntimicrobial Agents and Chemotherapy, 2007
- Prophylaxis and Therapy of Inhalational Anthrax by a Novel Monoclonal Antibody to Protective Antigen That Mimics Vaccine-Induced ImmunityInfection and Immunity, 2006
- Bacillus anthracisSpores Stimulate Cytokine and Chemokine Innate Immune Responses in Human Alveolar Macrophages through Multiple Mitogen-Activated Protein Kinase PathwaysInfection and Immunity, 2006
- Sverdlovsk revisited: Modeling human inhalation anthraxProceedings of the National Academy of Sciences, 2006